Who is sponsoring NCT04791514?

NCT04791514 is sponsored by Insmed Incorporated.

What drugs are being tested in NCT04791514?

Interventions in NCT04791514: Treprostinil Palmitil.

What condition does NCT04791514 study?

NCT04791514 studies Pulmonary Arterial Hypertension.

Is NCT04791514 still recruiting?

NCT04791514 is currently terminated. Last updated 22 September 2023.

Are results published for NCT04791514?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2023-09-22 · How we verify

NCT04791514

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH)

Terminated Phase 2 Results posted Last updated 22 September 2023

What this trial tests

Phase 2 trial testing Treprostinil Palmitil in Pulmonary Arterial Hypertension in 1 participant. Terminated before completion.

Timeline

29 March 2022

Primary endpoint
26 August 2022

26 August 2022

Quick facts

Lead sponsor	Insmed Incorporated
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	1
Start date	29 March 2022
Primary completion	26 August 2022
Estimated completion	26 August 2022
Sites	1 location across United States

Drugs / interventions tested

Treprostinil Palmitil — full drug profile →

Conditions studied

Pulmonary Arterial Hypertension — all drugs for Pulmonary Arterial Hypertension →

Sponsor

Insmed Incorporated — full company profile →

Who can join

18 and older, any sex, with Pulmonary Arterial Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main purpose of this study is to evaluate the safety and tolerability of single dose of treprostinil palmitil inhalation powder (TPIP) in participants with pulmonary arterial hypertension (PAH).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Future Perspectives of Pulmonary Arterial Hypertension: A Review of Novel Pipeline Treatments and Indications.
Novara ME, Di Martino E, Stephens B, Nayrouz M, et al · · 2024 · cited 6× · PMID 38514585 · DOI 10.1007/s40268-024-00453-x

Verify or expand the search:

Other trials of Treprostinil Palmitil

Trials testing the same drug.

NCT05649748 — An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH) · Phase 2, PHASE3 · active not recruiting
NCT05176951 — A Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonar · Phase 2 · completed
NCT05147805 — A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants · Phase 2 · completed
NCT06939647 — An Expanded Access Study to Assess Treprostinil Palmitil Inhalation Powder (TPIP) for Participants With Pulmonary Arteri · available

Other recruiting trials for Pulmonary Arterial Hypertension

Currently open trials in the same condition.

NCT07391228 — Cognitive Alterations in Pulmonary Arterial Hypertension (PAH) · active not recruiting
NCT06351345 — 129 Xenon Imaging in Patients Treated With Sotatercept · Phase 2 · recruiting
NCT07217522 — Rutgers University Study of the Genetics of Pulmonary Hypertension · recruiting
NCT07013149 — The Impact of ERA Switching on Risk Stratification in Pulmonary Arterial Hypertension · recruiting
NCT06658522 — Right Ventricular Compensation With Sotatercept: A Prospective Single Arm Open Label Phase 4 Study to Evaluate the Effec · Phase 4 · recruiting

Other Insmed Incorporated trials

Trials by the same sponsor.

NCT07481981 — A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants · Phase 3 · not yet recruiting
NCT07234032 — An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertens · Phase 3 · not yet recruiting
NCT07179380 — Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension · Phase 3 · recruiting
NCT07102316 — A Study to Assess the Relative Bioavailability After a Single Inhalation Administration of Treprostinil Palmitil Inhalat · Phase 1 · completed
NCT06685835 — A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS) · Phase 2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04791514 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Insmed Incorporated
Last refreshed: 22 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04791514.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing